Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

被引：0
|
作者：
Bell, Jill A. [1 ]
Cherepanov, Dasha [1 ]
Revicki, Dennis [2 ]
Speck, Rebecca M. [2 ]
Swett, Laura [2 ]
Stumpo, Kate [1 ]
Rong, Yuanxin [1 ]
Gordon, Leo I. [3 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Evidera PPD, Bethesda, MD USA
[3] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
QUALITY OF LIFE RESEARCH | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
B204.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [31] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
    Saverno, Kim
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Epperla, Narendranath
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
  • [32] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
    Schuster, Stephen J.
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
  • [33] First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.
    Neelapu, Sattva Swarup
    Munoz, Javier
    Locke, Frederick Lundry
    Miklos, David Bernard
    Brown, Robert
    McDevitt, Jennifer T.
    Mardiros, Armen
    Demirhan, Eren
    Konto, Cyril
    Tees, Michael Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).
    Zelenetz, Andrew David
    Jagadeesh, Deepa
    Reddy, Nishitha M.
    Stathis, Anastasios
    Salman, Huda S.
    Asch, Adam Steven
    Kenkre, Vaishalee Padgaonkar
    Jhangiani, Haresh S.
    Iasonos, Alexia
    Soumerai, Jacob D.
    Llorin, Judith
    Pagel, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.
    Leppa, Sirpa
    Santoro, Armando
    Demeter, Judit
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Mollica, Luigina
    Nagler, Arnon
    Diong, Colin Phipps
    Provencio, Mariano
    Stevens, Don A.
    Trevarthen, David R.
    Wang, MingLu
    Wirtz, Oliver
    Miriyala, Ashok
    Vargas, Jose Garcia
    Childs, Barrett H.
    Zinzani, Pier Luigi
    Dreyling, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [38] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
    Chong, Geoffrey
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Villasboas, Jose C.
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Tucker, David
    Walewski, Jan
    Song, Yuqin
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Luminari, Stefano
    Mayer, Laura Magnano
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jingxian
    Uppala, Amulya
    Shariff, Saleem
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Kim, Tae Min
    CANCER RESEARCH, 2024, 84 (07)
  • [39] THE CURE MYTH: EXPERIENCE FROM RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
    Mohseninejad, L.
    Hardy, A.
    Westley, T.
    Kongnakorn, T.
    VALUE IN HEALTH, 2022, 25 (01) : S8 - S8
  • [40] PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Rivas, A.
    Gonzalez, B.
    Martinez-Trillos, A.
    Martinez, A.
    Delgado, J.
    Gine, E.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2016, 101 : 273 - 274
12345